Tesla, Inc. vs 10X Genomics Inc — how do they compare? Tesla, Inc. trades at $334.01 (market cap $1.31T), while 10X Genomics Inc trades at $58.7 (market cap $7.61B). The key difference: Tesla, Inc. is far larger — about 172.1× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| TSLA | TXG | |
|---|---|---|
Market Cap | $1.31T | $7.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $489.88 | $58.57 |
52-Week Low | $298.16 | $11.34 |
Enterprise Value | $1.29T | $7.14B |
Signals from Pluang's Aura AI — not financial advice
Tesla (TSLA) trades at $330.87, up 0.7% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key resistance at $333 and support at $327, while fundamentals reveal high valuation multiples (P/E 306.37) and declining profit margins (net margin 3.67% in 2025). Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, balancing near-term delivery misses with long-term innovation bets.
Tesla's outlook hinges on executing its pivot to AI and autonomy amid slowing auto growth. Investment opportunities lie in market leadership in self-driving technology and energy expansion, but risks include intense EV competition, execution challenges, and rich valuations that demand flawless growth. Wall Street remains divided, with a $393.87 consensus target suggesting upside if catalysts materialize.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →